OncoPharm podkast

Paradigm and Daraxonrasib in NSCLC

3.09.2026
0:00
14:31
Do tyłu o 15 sekund
Do przodu o 15 sekund
PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML. Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Więcej odcinków z kanału "OncoPharm"